Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

ABEONA THERAPEUTICS INC. ABEO

· Materials · Pharmaceutical Preparations

FY2025 10-K, filed 2026-03-17
SEC EDGAR

Filing evidence summary

Mixed evidenceCoverage 5/5 core metrics

Operating margin changed -190.2 percentage points from the prior annual period.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • Operating margin compressed

    Operating margin changed -190.2 percentage points from the prior annual period.

    Why this surfaced

    Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.

  • Free cash flow was negative

    Latest reported free cash flow was -$84M.

    Why this surfaced

    Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.

  • 5 filing risk checks flagged

    Flagged areas: Earnings quality, Solvency & liquidity, Dilution.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

  • Revenue expanded

    Latest reported annual revenue changed +66.3% from the prior reported annual observation.

    Why this surfaced

    Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.

Core trend metrics

Latest annual revenue growth
+66.3%
as of 2025-12-31
Latest annual operating margin
-1536.9%
as of 2025-12-31
Free cash flow
-$84M
as of 2025-12-31
Debt / equity
0.13x
as of 2025-12-31
ROIC snapshot
-54.5%
period varies

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

5of 10 rule-based checks flagged
  • Earnings quality
  • Solvency & liquidity
  • Dilution

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-09-06
Latest period end
2025-12-31
Filings
EDGAR ↗

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-03-17prior period 2024-12-31 from the same filingView filing
By product or service
Revenue
  • License$3.4M
    58.4%
    no prior
  • Product$2.42M
    41.6%
    no prior

Members sum to the consolidated $5.82M for this period.

Latest quarter
Quarter ending 2026-03-3110-Q filed 2026-05-13prior period 2025-03-31 from the same filingView filing
  • Product$8.72M
    100.0%
    no prior

Change is against the same quarter a year earlier, as reported in the same 10-Q.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

Peer percentiles

latest fiscal year ending 2025-12-31 · among 4,144 US-listed filers · 804 in Materials
MetricValuevs all filersvs sector
Revenue
latest fiscal-year revenue as filed
$6M
9thof 3,302
bottom third
19thof 522
bottom third
Operating margin
operating income ÷ revenue
-1536.9%
5thof 2,820
bottom third
17thof 483
bottom third
Net margin
net income ÷ revenue
1223.1%
99thof 3,264
top third
100thof 518
top third
Free-cash-flow margin
(operating cash flow − |capex|) ÷ revenue
-1448.5%
4thof 2,680
bottom third
13thof 433
bottom third
Return on equity
net income ÷ stockholders' equity (positive equity only)
44.7%
96thof 3,578
top third
98thof 701
top third
Interest coverage
operating income ÷ interest expense (interest expense > 0)
-23.9×
14thof 819
bottom third
34thof 155
middle third
Stock comp ÷ revenue
stock-based compensation ÷ revenue · lower is ranked higher
185.2%
5thof 2,896
bottom third
15thof 476
bottom third
Days sales outstanding
receivables ÷ revenue × 365 · lower is ranked higher
386 days
1stof 2,399
bottom third
2ndof 387
bottom third
Cash conversion
operating cash flow ÷ net income (net income > 0)
-1.1×
3rdof 2,253
bottom third
4thof 193
bottom third
Cash-flow accrual ratio
(net income − operating cash flow) ÷ average total assets · lower is ranked higher
89.8%
0thof 3,874
bottom third
1stof 760
bottom third
Balance-sheet accrual ratio
change in net operating assets ÷ average net operating assets · lower is ranked higher
87.1%
12thof 3,321
bottom third
19thof 669
bottom third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

latest fiscal year ending 2025-12-31 · accruals and cash conversion as filed
Cash conversion
-1.07×
operating cash flow ÷ net income, latest fiscal year
Cash-flow accrual ratio
89.8%
(net income − operating cash flow) ÷ average total assets
Balance-sheet accrual ratio
87.1%
change in net operating assets ÷ average net operating assets
Cash-backed years
3 of 5
fiscal years where operating cash flow met or exceeded net income
Mean cash conversion
-1.07×
across the stored fiscal years with positive net income

Per fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.

Point-in-time ledger

first-reported vs latest filing · periods since 2020-01-01 · 9 changed periods
Line itemPeriodFirst reportedLatest filingChangeFilings
Net income
NetIncomeLoss
quarter 2022-06-30-$8.29M
10-Q 2022-08-11
-$4.1M
10-Q 2023-08-08
+50.6%first · latest
Interest expense
InterestExpense
quarter 2022-06-30$317K
10-Q 2022-08-11
$200K
10-Q 2023-08-08
-36.9%first · latest
Stockholders' equity
StockholdersEquity
balance at 2022-03-31$31.4M
10-Q 2022-05-13
$21.2M
10-Q 2023-08-08
-32.6%first · latest · 4 filings carry it
Net income
NetIncomeLoss
quarter 2022-09-30-$9.48M
10-Q 2022-11-14
-$6.43M
10-Q 2023-11-13
+32.2%first · latest
Total liabilities
Liabilities
balance at 2021-12-31$28.2M
10-K 2022-03-31
$37.2M
10-K 2023-03-29
+31.9%first · latest · 5 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2022-06-30$20.1M
10-Q 2022-08-11
$14M
10-Q 2023-11-13
-30.2%first · latest · 4 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2022-09-30$15.4M
10-Q 2022-11-14
$12.4M
10-Q 2023-11-13
-19.5%first · latest
Stockholders' equity
StockholdersEquity
balance at 2021-12-31$51.4M
10-K 2022-03-31
$42.4M
10-K 2024-03-18
-17.5%first · latest · 9 filings carry it
Net income
NetIncomeLoss
quarter 2022-03-31-$20.8M
10-Q 2022-05-13
-$22M
10-Q 2023-05-11
-6.0%first · latest

1 share-count period re-presented for a stock split (1-for-25) are listed apart from restatements and not counted above.

First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.

Notes by disclosure type

Not available for ABEO yet: no footnote text blocks on file for this filer in the ingested DERA files.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.